Abstract
A dosage of 1 g of valacyclovir 3 times per day (TID) for 7 days has already been shown to be superior to an oral dosage of 800 mg acyclovir 5 times per day for 7 days in immunocompetent individuals. The objective of this study was to assess the safety and efficacy of an oral dosage of valacyclovir, 1 g TID versus 2 g TID, for the treatment of herpes zoster in immunocompromised patients > or =18 years of age. The oral dosage schedule of 2 g of valacyclovir TID reaches acyclovir plasma levels similar to those achieved with intravenous acyclovir therapy given to immunocompromised patients (10 mg/kg every 8 h for 7 days). In this double-blind study, 87 immunocompromised patients with clinical evidence of localized herpes zoster were randomized to receive oral valacyclovir therapy for 7 days, either 1 g TID or 2 g TID, within 72 h after onset of zoster rash. Patients were seen and assessed for cutaneous healing, zoster-associated pain (ZAP), and/or zoster-associated abnormal sensations (ZAAS), up to 24 weeks. Participants in both arms of the study demonstrated similar median times to full crusting of the rash (8 days), and both dosages were safe and effective therapies for reduction of ZAP and ZAAS in the immunocompromised patient ...Continue Reading
References
Jan 23, 1986·The New England Journal of Medicine·D H SheppJ D Meyers
Jan 1, 1987·Current Eye Research·M CoboD B Jones
Nov 1, 1971·American Journal of Epidemiology·B B Wentworth, E R Alexander
Jun 1, 1980·Neurology·A E Miller
Jun 16, 1983·The New England Journal of Medicine·H H BalfourR E Keeney
Sep 1, 1982·Medicine·M W RagozzinoH O Perry
Jul 1, 1995·Antimicrobial Agents and Chemotherapy·K R BeutnerM J Wood
Jul 4, 1996·The New England Journal of Medicine·R G Kost, S E Straus
Dec 1, 1995·Antiviral Research·K R Beutner
Nov 14, 1997·Medicine·W R BellJ E Feinberg
Feb 12, 1998·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·K V RolstonE B Rubenstein
Apr 9, 2001·Cancer Investigation·S TyringUNKNOWN Colaborative Famciclovir Immunocompromised Study Group
Feb 1, 1957·A.M.A. Archives of Dermatology·J M DE MORAGAS, R R KIERLAND
May 18, 1957·Journal of the American Medical Association·C F BURGOONG D BALDRIDGE
Dec 18, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Sita GourishankarJutta K Preiksaitis
Citations
Apr 28, 2010·Bone Marrow Transplantation·A KleinD R Snydman
Dec 3, 2013·Expert Opinion on Pharmacotherapy·Sharon R KimStephen K Tyring
Jan 15, 2010·Current Medical Research and Opinion·Peter LeoneKamal Hamed
Jul 3, 2013·The Medical Clinics of North America·Kim M O'Connor, Douglas S Paauw
Mar 9, 2010·Enfermedades infecciosas y microbiología clínica·Montse TusetJosé M Miró
Aug 21, 2009·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·M B MustafaS R Porter
Oct 23, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Mar 8, 2013·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S A PergamUNKNOWN AST Infectious Diseases Community of Practice
Jan 28, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S A PergamUNKNOWN AST Infectious Diseases Community of Practice
Nov 15, 2016·The Cochrane Database of Systematic Reviews·Alexander K SchusterJonas Tesarz
Apr 9, 2009·Expert Opinion on Pharmacotherapy·David G Partridge, Michael W McKendrick
Jun 5, 2019·Clinical Transplantation·Steven A PergamUNKNOWN AST Infectious Diseases Community of Practice
May 1, 2020·Open Forum Infectious Diseases·Sean Moss, Helen W Boucher
Mar 9, 2018·Indian Journal of Dermatology, Venereology and Leprology·Elsam KoshyWu Jianbo